Trial · NCT04051606
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
NCT04051606, Phase 2, Completed, Case Comprehensive Cancer Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma. Trials, record NCT04051606. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04051606
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
- NCT number
- NCT04051606
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 14 participants, actual
- Lead sponsor
- Case Comprehensive Cancer Center
- Conditions
- Recurrent Glioblastoma
- Interventions
- Regorafenib
- First posted
- 2019-08-09
- Last updated
- 2025-06-05
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Median overall survival (OS) | Up to 3 years from start of treatment | Median overall survival (OS) in patients with recurrent or progressive GBM who have progressed on bevacizumab. |
| Secondary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Up to 3 years from start of treatment | Safety and tolerability of regorafenib by CTCAE version 5.0. Safety and tolerability will be defined by the percent of participants experiencing \>= grade 3 AE/SAE |
| Secondary | Objective response rate (ORR) | Up to 3 years from start of treatment | ORR by modified RANO criteria. ORR defined by modified RANO criteria . The percentage of patients that have at least 50% reduction in their tumor size in 2 dimensions. |
| Secondary | Progression free survival at 6 months (PFS-6). | at 6 months from start of treatment | Survival and absence of progressive disease at 6 months, with progression defined as \>25% in the sum of products of the perpendicular diameters of CE lesions; evidence of new lesion(s). |
| Secondary | Median time to progression (TTP) | Up to 3 years from start of treatment | Time that takes a median patient to progress defined as \>25% in the sum of products of the perpendicular diameters of CE lesions; evidence of new lesion(s). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42325608 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04051606
GET https://conductscience.org/api/trials/v1/NCT04051606/registered